Polyrizon Ltd (PLRZ)
10.65
-0.74 (6.50%)
Upcoming Events
Latest Headlines
Form D Polyrizon Ltd.
September 10, 2026 4:15 PM - SEC Filing
Polyrizon launches $4M registered direct offering and private placement
September 3, 2026 8:50 AM - StreetInsider
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
September 3, 2026 8:50 AM - StreetInsider
Polyrizon signs all five U.S. sites for NASARIX allergy trial
September 2, 2026 7:32 AM - StreetInsider
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
September 2, 2026 7:32 AM - StreetInsider
Form 6-K Polyrizon Ltd. For: Aug 20
August 20, 2026 4:00 PM - SEC Filing
Polyrizon completes site contracts for Nasarix allergy trial
August 20, 2026 9:30 AM - StreetInsider
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
August 20, 2026 9:30 AM - StreetInsider
Form SCHEDULE 13G/A Polyrizon Ltd. Filed by: MMCAP International Inc. SPC
August 14, 2026 3:17 PM - SEC Filing
Form 6-K Polyrizon Ltd. For: Jul 13
July 13, 2026 4:01 PM - SEC Filing
Core AI Holdings names Arie Goor as CFO, effective July 1
July 7, 2026 8:20 AM - StreetInsider
Form 6-K Polyrizon Ltd. For: Jul 02
July 2, 2026 4:01 PM - SEC Filing
Polyrizon completes biocompatibility tests for NASARIX nasal spray
July 2, 2026 7:34 AM - StreetInsider
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
July 2, 2026 7:32 AM - StreetInsider
Form 6-K Polyrizon Ltd. For: Jun 29
June 29, 2026 4:01 PM - SEC Filing
Polyrizon gets IRB approval for NASARIX allergy blocker trial
June 29, 2026 8:45 AM - StreetInsider
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
June 29, 2026 8:44 AM - StreetInsider
Full Article List
